Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Epigenetic Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KAT6B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KAT6B Active Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View KAT6B Products |
| Gene Delivery | KAT6B Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View KAT6B Products |
| Benchmark Ab | Anti-KAT6B Antibody Recombinant positive control for western blot and target engagement. |
View KAT6B Products |
| Validator | KAT6B siRNA Set For knockdown verification and specificity profiling. |
View KAT6B Products |
| Related Target A | KAT6A Paralog and frequent co-target in dual KAT6A/B inhibitor development. |
View KAT6A Products |
| Related Target B | BRPF1 Essential scaffolding protein for the KAT6 histone acetyltransferase complex. |
View BRPF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| KAT Family Selectivity Profiling (KAT6A vs KAT6B) | Human KAT6A and KAT6B ortholog proteins available with >95% purity and verified theoretical MW. |
| Enzymatic Assay Stability | Structurally verified catalytic domains expressed in optimized systems to preserve native folding. |
| Lack of Controls | Clinical Benchmark Antibodies included for robust assay standardization. |
| False Positives in Screening | Validated siRNA included for cellular specificity and knockdown checks. |
Live KAT6B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KAT6B therapeutics is intensifying, with major players shifting focus toward dual KAT6A/B inhibitors in oncology, particularly in hormone receptor-positive breast cancer and other epigenetically driven malignancies. As first-generation small molecules reach the clinic, the next wave of R&D is targeting selective degraders (PROTACs) and overcoming emerging resistance mechanisms in the epigenetic landscape.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Pfizer, Monash University | ER+ Breast Cancer, Prostate Cancer | Enzymatic Selectivity (Need high-purity KAT6A/B domains) |
| PROTACs / Degraders | Academic Consortia, Biotechs | Advanced Solid Tumors | Target Engagement & Degradation Assays (Need benchmark Abs & precise proteins) |
| Combination Therapy | Various Big Pharma | Endocrine Therapy Resistant Cancers | Pathway profiling (Need related targets like BRPF1 and ER pathway markers) |